Chinese biotech BioGeometry secures over $100 million Series A for AI-driven protein design

BioGeometry, a four-year-old biotech startup based in Beijing, announced it has closed a Series A financing round of more than $100 million.

The capital will be used to expand its artificial-intelligence platform that designs proteins for drug development, the company said in a statement on Wednesday.

The sizable raise underscores growing investor interest in AI-driven approaches to pharmaceutical research in China and could accelerate BioGeometry’s pipeline.